QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, May 20, 2009, 29(20):6545-6557; doi:10.1523/JNEUROSCI.0421-09.2009

This Article Full Text Full Text (PDF) Supplemental Data Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in J. Neurosci. Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by He, P. Articles by Shen, Y. PubMed PubMed Citation Articles by He, P. Articles by Shen, Y.

 Previous Article  |  Next Article 

Development/Plasticity/Repair
Interruption of β-Catenin Signaling Reduces Neurogenesis in Alzheimer's Disease

Ping He and Yong Shen

Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, Sun City, Arizona 85351

Correspondence should be addressed to Dr. Yong Shen, Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351. Email: yong.shen{at}bannerhealth.com

The neuronal loss associated with Alzheimer's disease (AD) affects areas of the brain that are vital to cognition. Although recent studies have shown that new neurons can be generated from progenitor cells in the neocortices of healthy adults, the neurogenic potential of the stem/progenitor cells of AD patients is not known. To answer this question, we compared the properties of glial progenitor cells (GPCs) from the cortices of healthy control (HC) and AD subjects. The GPCs from AD brain samples displayed reduced renewal capability and reduced neurogenesis compared with GPCs from HC brains. To investigate the mechanisms underlying this difference, we compared β-catenin signaling proteins in GPCs from AD versus HC subjects and studied the effect of amyloid β peptide (Aβ, a hallmark of AD pathology) on GPCs. Interestingly, GPCs from AD patients exhibited elevated levels of glycogen synthase kinase 3β (GSK-3β, an enzyme known to phosphorylate β-catenin), accompanied by an increase in phosphorylated β-catenin and a decrease in nonphosphorylated β-catenin compared with HC counterparts. Furthermore. we found that Aβ treatment impaired the ability of GPCs from HC subjects to generate new neurons and caused changes in β-catenin signaling proteins similar to those observed in GPCs from AD patients. Similar results were observed in GPCs isolated from AD transgenic mice. These results suggest that Aβ-induced interruption of β-catenin signaling may contribute to the impairment of neurogenesis in AD progenitor cells.

---

Received Jan. 26, 2009; revised April 15, 2009; accepted April 15, 2009.

Correspondence should be addressed to Dr. Yong Shen, Haldeman Laboratory of Molecular and Cellular Neurobiology, Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351. Email: yong.shen{at}bannerhealth.com

Related articles in J. Neurosci.:

Alzheimer's Disease Affects Progenitor Cells through Aberrant β-Catenin Signaling

Muhammad Amir Khan and Lucia Berti
J. Neurosci. 2009 29: 12369-12371. [Full Text]  

This article has been cited by other articles:

				M. A. Khan and L. Berti Alzheimer's Disease Affects Progenitor Cells through Aberrant {beta}-Catenin Signaling J. Neurosci., October 7, 2009; 29(40): 12369 - 12371. [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help